Navigation Links
Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
Date:2/20/2008

SOUTH SAN FRANCISCO, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has earned a preclinical milestone payment from Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) under the companies' drug discovery collaboration agreement.

The two companies entered into a research collaboration in May 2002 to discover oral small molecule enzyme inhibitors for the treatment of major chronic inflammatory and autoimmune diseases. The recent milestone payment was triggered by J&JPRD's selection of a compound targeting the Cathepsin S enzyme as a development candidate. Under the terms of the collaboration agreement, Sunesis has the potential to receive additional development milestone payments from J&JPRD, as well as royalty payments based on future product sales.

"We believe that a small molecule inhibitor of Cathepsin S will provide a useful approach to treating certain inflammatory conditions and we are pleased by J&JPRD's advancement of a compound from our collaboration into development," said Bob McDowell, Ph.D., Vice President of Research at Sunesis.

About Cathepsin S

Cathepsin S is an enzyme involved in the activation of immune system T-cells. Inhibiting inappropriate activation of T-cells may lead to novel treatments of certain inflammatory and autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
2. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
4. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
5. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
6. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
7. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
8. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
9. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
10. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
11. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... involve a range of resource and environmental problems. ... resin and a clever recycling strategy, Uppsala researchers ... alternative. Their study will be presented soon in ... think our discovery can open several doors to ... the future, says Daniel Brandell, Associate Professor at ...
(Date:9/29/2014)... , September 29, 2014 ... research report "Epigenetics Market by Product (Modifying Enzymes, ... Kit, Bisulphite Conversion Kit, Reagents), by Research ... - Global Forecast to 2019", published by ... major drivers, restraints, opportunities, current market trends, ...
(Date:9/29/2014)... 29, 2014 ACEA Biosciences, Inc. ... the 2014 iCELLigence Research Grant for his proposal ... instrument is an impedance based real-time label-free cellular ... Department of Biomedical Engineering at Yale University currently ... projects in Professor Rong Fan's laboratory ...
(Date:9/29/2014)... YORK , Sept. 29, 2014 ... and The Channel Group ("TCG"), a leader in ... advisors, have formed an alliance to expand the ... prospective clients. With the alliance, Burnham Securities will ... the scientific, clinical medicine and management in healthcare ...
Breaking Biology Technology:Smart, eco-friendly new battery to solve problems 2Epigenetics Market Worth $783.17 Million by 2019 2Epigenetics Market Worth $783.17 Million by 2019 3Epigenetics Market Worth $783.17 Million by 2019 4ACEA Biosciences, Inc. Awards Yale University Researcher the iCELLigence Research Grant 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 3
... Companies will Present at the Largest Marketplace for Emerging ... and CTSI today announced that more than 100 leading ... partners will be showcased in the 4th Annual TechConnect ... R. Brown Convention Center in Houston, Texas. Held ...
... Development and InnovationMOUNTAIN VIEW, Calif., April 22 ... Pharmaceuticals & Biotechnology group assesses a variety of ... in cancer treatment. Physicians, nurses and patients ... reconstitution, home vs. office administration parameters, and barriers ...
... 22 GeneGo, Inc., a leading provider of software ... , today announced that the University of Cardiff has ... researchers will have access to GeneGo,s MetaCore, training and ... their partner relationship with GeneGo to provide a pathway ...
Cached Biology Technology:TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 2TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 3TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 4Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males 2Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males 3Cardiff University Becomes a GeneGo Center of Excellence 2
(Date:9/29/2014)... In order to support the world,s needs to ... and more, new and more efficient catalytic materials ... researchers, including several from Wayne State University, is ... new grant from the National Science Foundation. , ... of Multicomponent Materials for Electrocatalytic Cascade Reactions," was ...
(Date:9/29/2014)... five-year, $6 million grant for clinical research and ... of safe and effective treatments for cocaine addiction. ... Institutes of Health, National Institute on Drug Abuse, ... for Cocaine Use Disorder to oversee preclinical and ... moving forward with more expensive large-scale clinical trials. ...
(Date:9/29/2014)... A review article published online in Behavioral ... happen in the brain as a result of chronic ... sleep cycle. , Clinical assessments and research indicate ... severely disrupted sleep. This can occur when people are ... when they are abstaining. , "Sleep-wake disturbances can ...
Breaking Biology News(10 mins):Wayne State research aims to develop new, more efficient catalytic materials 2New VCU center to target cocaine addiction 2
... EMBO announced today the selection of 23 young ... network of 315 current and past Young Investigators. ... years of age who have established their first laboratories ... in ten European countries, Israel and Singapore. The success ...
... the University of Sheffield,s Faculty of Engineering, have shown ... turning it into glass reduces its volume by 85-95 ... plutonium, creating a stable end product. The approach ... wastes generated during the eventual clean-up of the damaged ...
... to find the necessities of life. It,s a complex task, ... environment to navigate the safest and fastest routes to food ... certain important events, such as finding a meal, will occur. ... fundamental behaviors, navigation and the anticipation of a reward, had ...
Cached Biology News:Volume of nuclear waste could be reduced by 90 percent, says new research 2Anticipation and navigation: Do your legs know what your tongue is doing? 2Anticipation and navigation: Do your legs know what your tongue is doing? 3Anticipation and navigation: Do your legs know what your tongue is doing? 4
FGF Receptor 1 Antibody...
Rabbit polyclonal to Kallikrein 1 ( Abpromise for all tested applications). Antigen: Full length native kallikrein from tissue (Human) Entrez Gene ID: 3816 Swiss Protein ID: P06870...
EDG-1CT (endothelial cell differentiation gene-1, C terminal)...
Mouse monoclonal [1-N-14] to Adenovirus Type 7 hexon C11 Immunogen: Purified Adenovirus type 7 Specificity: This antibody is specific for Adenovirus type 7 hexon C11....
Biology Products: